Vaccine maker Serum Institute of India could soon export nearly one crore of doses of its covid-19 jab Covovax, official sources told News18.com. About 97 lakh doses have been cleared by the nation’s top testing laboratory, the Central Drugs Laboratory in Kasauli, after testing for safety and efficacy. The lots are now awaiting completion of the documentation formalities.
US vaccine manufacturer Novavax Inc has entered into a licensing agreement with SII for the development and commercialization of NVX-CoV2373, its candidate vaccine against Covid-19. Covovax is not yet approved by the Indian medicines regulator and is also being evaluated for an emergency use list at the World Health Organization (WHO).
Batches of the Covid-19 vaccine made from recombinant protein nanoparticles with Matrix-M adjuvant will likely be exported to the Philippines and Indonesia, two countries where the vaccine has so far been approved under an “authorization to” ’emergency use’. Both countries had approved the vaccines for emergency use in November.
“About 97 lakh doses are cleared by the Himachal Pradesh Central Medicines Laboratory and have been cleared for export,” an official from the Department of Health and Family Welfare told News18.com. “The doses will be exported to two countries which donated the EUA,” they added.
According to the senior government official, at least 50 lakh doses will be exported to Indonesia and the rest will be sent to the Philippines. These will be commercial exports.
On May 21, the SII filed an application with the Drugs Controller General of India (DCGI) for authorization for the emergency use of Covovax. However, it is still awaiting approval from the drug regulatory authority, as the expert panel has requested more information.
Read all the latest news, breaking news and news on the coronavirus here.